Which medication must be on the discharge list of a patient admitted for CHF?

In the context of heart failure, particularly congestive heart failure (CHF), the use of angiotensin-converting enzyme (ACE) inhibitors is a common and crucial aspect of management. Lisinopril, which is an ACE inhibitor, is known for its ability to decrease morbidity and mortality in patients with heart failure. It works by preventing the conversion of angiotensin I to angiotensin II, leading to vasodilation, reduced blood pressure, and decreased afterload on the heart, which ultimately helps improve cardiac function and reduces symptoms of heart failure.

In the discharge planning for a patient with CHF, it is essential to ensure that patients are well-managed on appropriate heart failure therapies, and ACE inhibitors like lisinopril are key components of guideline-directed medical therapy to prevent hospital readmission and improve quality of life.

While other medications listed, such as Norvasc (a calcium channel blocker) or Losartan (an angiotensin II receptor blocker), can play roles in cardiovascular management, they do not have the same established benefits in the specific context of CHF as an ACE inhibitor like lisinopril does. Thus, including lisinopril on the discharge list is critical for optimal management of a patient who has been admitted for